Yuh-Min Chen
Overview
Explore the profile of Yuh-Min Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
243
Citations
4816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tseng Y, Ho C, Chian C, Chiang C, Chao H, Tsai C, et al.
Sci Rep
. 2024 Aug;
14(1):19374.
PMID: 39169058
The 5-year survival is poor for stage IV non-small cell lung cancer (NSCLC). Recently, cell immunotherapy has emerged as a new treatment strategy. This study aimed to evaluate the efficacy...
12.
Laah A, Tsai P, Yarmishyn A, Ching L, Chen C, Chien Y, et al.
Adv Sci (Weinh)
. 2024 Aug;
11(38):e2400370.
PMID: 39113226
NK2 Homeobox 1 (NKX2-1) is a well-characterized pathological marker that delineates lung adenocarcinoma (LUAD) progression. The advancement of LUAD is influenced by the immune tumor microenvironment through paracrine signaling. However,...
13.
Tseng Y, Pan S, Huang J, Lee C, Hung J, Hsu P, et al.
Microb Cell
. 2024 Jul;
11:278.
PMID: 39081906
The PD-1/PD-L1 pathway plays a pivotal role in T cell activity and is involved in the pathophysiology of (MTB) infection. DNA methylation is a mechanism that modulates PD-L1 expression in...
14.
Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, et al.
medRxiv
. 2024 Jul;
PMID: 38978671
Polygenic risk scores (PRSs) are promising for risk stratification but have mainly been developed in European populations. This study developed single- and multi-ancestry PRSs for lung adenocarcinoma (LUAD) in East...
15.
Wang T, Hong J, Chiu H, Chao H, Chen Y, Wu Y
Eur Radiol
. 2024 May;
34(11):7397-7407.
PMID: 38777902
Purpose: To compare the diagnostic performance of standalone deep learning (DL) algorithms and human experts in lung cancer detection on chest computed tomography (CT) scans. Materials And Methods: This study...
16.
Chang G, Shih J, Yu C, Chao H, Yang C, Lin C, et al.
PLoS One
. 2024 May;
19(5):e0303046.
PMID: 38753697
Osimertinib has demonstrated efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) in clinical trials. However, real-world data on its effectiveness remain scarce. Taiwanese...
17.
Lo P, Feng J, Hsiao Y, Su K, Chou K, Chen Y, et al.
Respir Res
. 2024 May;
25(1):209.
PMID: 38750527
Background: Limited research has investigated the relationship between small airway dysfunction (SAD) and static lung hyperinflation (SLH) in patients with post-acute sequelae of COVID-19 (PASC) especially dyspnea and fatigue. Methods:...
18.
Shen H, Huang J, Sun C, Liao Y, Ko H, Chang C, et al.
Eur J Med Res
. 2024 Apr;
29(1):243.
PMID: 38643153
Background: Despite vaccines' effectiveness in reducing COVID-19 infection rates and disease severity, their impact on critical patients presenting with acute respiratory failure is elusive. The aim of this study was...
19.
Kato T, Yang J, Ahn M, Sakai H, Morise M, Chen Y, et al.
Br J Cancer
. 2024 Apr;
130(10):1679-1686.
PMID: 38575731
Background: Tepotinib, a MET inhibitor approved for the treatment of MET exon 14 (METex14) skipping NSCLC, demonstrated durable clinical activity in VISION (Cohort A + C; N = 313): objective...
20.
Tseng Y, Pan S, Feng J, Su W, Huang C, Chen Y
Tzu Chi Med J
. 2024 Feb;
36(1):67-75.
PMID: 38406566
Objectives: Determining a diagnosis for non- (NTM)-lung disease (LD) remains difficult. The value of circulating cell-free DNA (cfDNA) secreted from microbes has been established in the detection of pathogens in...